Vaxcyte Stock Forecast
NASDAQ: PCVXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
PCVX analyst consensus
Consensus (10 analysts)
strong_buy
Avg. price target
$110.88+65.59%
- Strong buy 1
- Buy 8
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 10 Wall Street analysts covering Vaxcyte (2026-10-07), 9 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $110.88, with a high estimate of $163.00 and a low estimate of $75.00. The average target implies upside of 65.6% from the current price of $66.96.
The spread between the highest and lowest targets is 117.3%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for PCVX.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 10% |
| Buy | 8 | 80% |
| Hold | 1 | 10% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $75.00 | +12.01% |
| Average target | $110.88 | +65.59% |
| High target | $163.00 | +143.43% |